Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lipid Particles Test Accurately Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 07 Apr 2011
A blood test for low-density lipoprotein (LDL) particles is a more accurate predictor of cardiovascular disease (CVD) events than LDL cholesterol (LDL-C). More...


A high value proprietary blood test using nuclear magnetic resonance (NMR) technology has demonstrated that the amount of cholesterol per low-density lipoprotein particle (LDL-P) is variable and related in part to particle size, with smaller particles carrying less cholesterol.

Scientists at Wake Forest University School of Medicine, (Winston-Salem, NC, USA), analyzed blood samples obtained at study onset from 5,598 middle-aged men and women free of cardiovascular disease, who participated in a prospective observational study. Participants were followed for a mean of 5.5 years for incident CVD events, including heart attack, coronary heart disease death, angina, stroke, stroke death, or other atherosclerotic or CVD death.

Of 319 total CVD events recorded, 159 occurred in persons with LDL-C and LDL-P numbers that disagreed. The CVD risk of these individuals tracked with LDL-P number regardless of levels of LDL-C and only LDL-P numbers were associated with incidence of CVD. LDL particle levels were measured using the NMR LipoProfile test (LipoScience Inc., Raleigh, NC, USA). LDL-P information can help clinicians personalize and refine LDL treatment decisions, particularly to minimize residual risk in patients with low LDL-C levels. Clinicians historically have used the LDL-C level, the amount of cholesterol carried within LDL particles, to determine how much treatment, if any, a patient needs.

David C. Goff, Jr., MD, PhD, an investigator in the study, said, "In many patients, the standard cholesterol test may not be sufficient to adequately manage LDL levels. Patients who achieve recommended LDL-C goals may not have achieved correspondingly low LDL-P levels and as a consequence, may need further LDL lowering." It is recommended that additional studies should be conducted to estimate the potential value of this information for the prevention of cardiovascular disease in the general population. The study was published online on February 14, 2011, in the Journal of Clinical Lipidology.

Related Links:
Wake Forest University
LipoScience Inc.





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.